Pure Global

Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D) - Trial NCT05509725

Access comprehensive clinical trial information for NCT05509725 through Pure Global AI's free database. This Phase 4 trial is sponsored by Lallemand Health Solutions and is currently Recruiting. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 162 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05509725
Phase 4
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT05509725
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D): A Multicenter, Randomized, Prospective, Placebo-Controlled, Double-Blind, Phase IV Clinical Study

Study Focus

Probiotic formulation

Interventional

drug

Sponsor & Location

Lallemand Health Solutions

ฤฐzmir, Turkey

Timeline & Enrollment

Phase 4

Aug 11, 2022

Sep 01, 2024

162 participants

Primary Outcome

Change in Abdominal Pain,Change in Defecation consistency

Summary

The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic
 formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and
 depression) as well as general quality of life in adults with IBS-D.

ICD-10 Classifications

Irritable bowel syndrome with predominant constipation [IBS-C]
Irritable bowel syndrome
Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Irritable bowel syndrome with mixed bowel habits [IBS-M]
Other and unspecified irritable bowel syndrome

Data Source

ClinicalTrials.gov

NCT05509725

Non-Device Trial